September 2023 Quarterly Activities Report & Appendix 4C
Released
Released
Announcement PDF
ASX Announcement
31 October 2023
Avecho Quarterly Activities Report and Appendix 4C
Melbourne, Australia, 31 October 2023: Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the
“Company”), focused on developing and commercialising innovative products using its proprietary Tocopheryl
Phosphate Mixture (“TPM®”) drug delivery system, is pleased to release its Quarterly Activities Report and
Appendix 4C for the quarter ended 30 September 2023.
Avecho CEO, Dr Paul Gavin, said:
“It was undoubtedly a key quarter for the business and investors as we concluded our capital raise. The
capital we were able to secure in the Placement announced in August 2023 allows us to proceed to the Phase
III clinical trial testing our oral CBD soft-gel capsule. The plans, timeline, and potential around this were
discussed on our recent investor webinar, which I’d encourage all shareholders to take the time to watch.”
A$6m Placement completed to allow commencement of Phase III Clinical Trial of CBD Soft-Gel
Capsule
Avecho received firm commitments from a range of sophisticated and institutional investors to raise A$6m
by way of a Placement during the reporting period.
This comprised of:
A first tranche of 536,128,321 fully paid ordinary shares, at an issue price of A$0.006 per New Share
to raise approximately ~A$3.2m;
A second tranche, conditional upon shareholder approval at a General Meeting to be held on 9
November 2023, to issue the balance of outstanding new shares at the same issue price, to raise
approximately ~A$2.8m.
Every two new shares in the Placement are accompanied by three free attaching options, exercisable at
$0.012 each, expiring on 10 May 2026.
The Placement is conducted on the same terms as Avecho’s entitlement offer announced to ASX on 3 April
2023 that raised ~A$2m from existing shareholders.
The funds raised in the Placement are to be used to advance Avecho’s pivotal phase III clinical trial of the
Company’s proprietary TPM® enhanced cannabidiol (“CBD”) soft-gel capsule to manage the symptoms of
insomnia. A small proportion of the funds will be allocated to general working capital and costs of the
Placement.
Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168
3440-6518-1734, v. 1
avecho.com.au
Phase III Clinical Trial Activities and Timelines
Manufacturing activities to support the pivotal Phase III clinical trial continue at US-based Contract
Manufacturing Organisation (“CMO”), Procaps Group (NASDAQ: PROC). Procaps is currently manufacturing
the capsule to be used in both the pivotal Phase III clinical trial, as well as the registration batches used to
demonstrate formal stability. The documentation from registration batches is a key component of a future
registration submission to the TGA or FDA and proves that the product can be manufactured reproducibly
with a pharmaceutically acceptable shelf life.
Further to the manufacturing, Avecho has now commenced the remaining activities required to begin the
Phase III trial. These include building the electronic database that will capture all the trial information from
patients, in addition to final preparations at the various sites. The trial will be conducted across 5 sites
around Australia; Melbourne, Brisbane, Perth, Western Sydney and Central Coast, NSW.
The capsules for use in the Phase III trial are expected to arrive in Australia during Q4 in order to be
randomized for use on study early in the new year. Patient recruitment and dosing is currently planned for
January 2024. The Company anticipates it will reach its interim analysis toward September or October 2024,
depending on the final rate of patient recruitment for the study.
The interim analysis will be a key milestone, allowing the company to review the data set for any observed
effect, and repower the study to determine how many remaining patients are required to maximise the
chance of a successful outcome. If no difference is seen between treatment groups, Avecho will not continue
to dose the remaining patients.
Phase III Clinical Trial Investor Webinar
Subsequent to the end of the period, Avecho’s CEO Dr Paul Gavin hosted a webinar to provide more detail
on the pivotal Phase III clinical trial, the accompanying activities and anticipated timelines mentioned above.
Avecho’s Phase III study testing its oral CBD softgel capsule for the treatment of insomnia will be the largest
of its kind to date and will compare nightly CBD doses of 75 and 150 mg CBD with placebo for their ability
to improve sleep.
To view a replay of the webinar, please visit the following link:
https://us02web.zoom.us/webinar/register/WN_srQ9CclRQG6ywB0JPpkEmw
Additional programs and partnerships
Avecho management has continued to further activities and discussions with current and prospective partners
during and subsequent to the end of the quarter. This included a business development roadshow to the US
where Avecho management met with numerous pharmaceutical and recreational cannabis companies. The
Company will update the market as these discussions materialise.
Corporate
During the quarter ended 30 September 2023, the Company had received a sum of ~A$3.2 million, net of
transaction fees, from the afore-mentioned Placement (Tranche 1).
In addition, during the quarter the Company invested ~A$955K in R&D activities and incurred administration
and corporate costs of ~A$360K. Administration and corporate costs during the quarter were higher
compared to historical amounts due to investor relationships and capital raising fees. At the end of the
quarter, the Company held ~A$4.74 million in cash.
2
3440-6518-1734, v. 1
Payments to related parties and their associates during the quarter, as outlined in Section 6 of the
accompanying Appendix 4C to this quarterly activities report, were ~A$53K.
For enquiries, please contact
Dr Paul Gavin
Chief Executive Officer
Avecho Biotechnology Limited
+61 3 9002 5000
This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.
About Avecho
Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products
using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM® is derived
from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and
oral, dermal and transdermal absorption of drugs and nutrients.
Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the
human health market and is also developing TPM® to enhance the feed efficiency and health of livestock.
See more here - avecho.com.au
Forward-Looking Statements
Certain statements in this announcement are forward looking statements. Forward looking statements can
generally be identified by the use of words such as “anticipate”, “estimate”, “expect”, “project”, “intend”,
“plan”, “believe”, “target”, “may”, “assume” and words of similar import. These forward-looking statements
speak only as at the date of this announcement. These statements are based on current expectations and
beliefs and, by their nature, are subject to a number of known and unknown risks and uncertainties that
could cause the actual results, performances and achievements to differ materially from any expected future
results, performance or achievements expressed or implied by such forward looking statements.
No representation, warranty or assurance (express or implied) is given or made by AVE that the forwardlooking statements contained in this announcement are accurate, complete, reliable or adequate or that they
will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, AVE and
its respective officers, employees and advisers expressly disclaim any responsibility for the accuracy or
completeness of the forward-looking statements and exclude all liability whatsoever (including negligence)
for any direct or indirect loss or damage which may be suffered by any person as a consequence of any
information in this announcement or any error or omission therefrom.
Subject to any continuing obligation under applicable law or relevant listing rules of the ASX, AVE disclaims
any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements in
these materials to reflect any change in expectations in relation to any forward-looking statements or any
change in events, conditions or circumstances on which any statement is based. Nothing in these materials
shall under any circumstances create an implication that there has been no change in the affairs of AVE since
the date of the announcement.
3
3440-6518-1734, v. 1
Rule 4.7B
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
AVECHO BIOTECHNOLOGY LIMITED
ABN
Quarter ended (“current quarter”)
32 056 482 403
30 September 2023
Consolidated statement of cash flows
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
Current quarter
$A’000
Year to date (9
months)
$A’000
25
735
(955)
(1,435)
(8)
(120)
(c) advertising and marketing
-
-
(d) leased assets
-
-
(e) staff costs*
39
(555)
(365)
(153)
(908)
(220)
(a) research and development
(b) product manufacturing and operating
costs
(f) administration and corporate costs
(g) patent portfolio costs
1.3
Dividends received (see note 3)
-
-
1.4
Interest received
7
12
1.5
Interest and other costs of finance paid
(3)
(9)
1.6
Income taxes paid
-
-
1.7
Government grants and tax incentives
-
687
1.8
Other (EMDG)
-
-
1.9
Net cash from / (used in) operating
activities
(1,413)
(1,813)
*A percentage of staff costs are reallocated to payments for research and development. Amounts
during the current quarter was adjusted to reflect the staff cost reallocation to payments for research
and development at 30 June 2023.
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
(h) entities
-
-
(i)
businesses
-
-
(j)
property, plant and equipment
-
-
-
-
(k) investments
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 1
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
(l)
2.2
Current quarter
$A’000
Year to date (9
months)
$A’000
intellectual property
-
-
(m) other non-current assets
-
-
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
Proceeds from disposal of:
other non-current assets
2.3
Cash flows from loans to other entities
-
-
2.4
Dividends received (see note 3)
-
-
2.5
Other (provide details if material)
-
-
2.6
Net cash from / (used in) investing
activities
-
-
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
3,217
5,163
3.2
Proceeds from issue of convertible debt
securities
-
-
3.3
Proceeds from exercise of options
-
-
3.4
Transaction costs related to issues of
equity securities or convertible debt
securities
(115)
(226)
3.5
Proceeds from borrowings
-
-
3.6
Repayment of borrowings
-
-
3.7
Transaction costs related to loans and
borrowings
-
-
3.8
Dividends paid
-
-
3.9(a)
Other – Payment of principal element of
lease liabilities
(17)
(52)
3.9(b)
Other – Advances for shares
197
197
3.10
Net cash from / (used in) financing
activities
3,282
5,082
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 2
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
Current quarter
$A’000
Year to date (9
months)
$A’000
2,868
1,468
(1,413)
(1,813)
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
4.3
Net cash from / (used in) investing activities
(item 2.6 above)
-
-
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
3,282
5,082
4.5
Effect of movement in exchange rates on
cash held
-
-
4.6
Cash and cash equivalents at end of
period
4,737
4,737
5.
Reconciliation of cash and cash
equivalents
Current quarter
$A’000
Previous quarter
$A’000
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
5.1
Bank balances
4,221
2,353
5.2
Call deposits
516
515
5.3
Bank overdrafts
-
-
5.4
Other (provide details)
-
-
5.5
Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
4,737
2,868
6.
Payments to related parties of the entity and their
associates
6.1
Aggregate amount of payments to related parties and their
associates included in item 1
(53)
6.2
Aggregate amount of payments to related parties and their
associates included in item 2
-
Current quarter
$A'000
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an
explanation for, such payments.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 3
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
7.
Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
$A’000
Amount drawn at
quarter end
$A’000
7.1
Loan facilities
-
-
7.2
Credit standby arrangements
-
-
7.3
Other (please specify)
-
-
7.4
Total financing facilities
-
-
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
-
N/A
8.
Estimated cash available for future operating activities
$A’000
8.1
Net cash from / (used in) operating activities (item 1.9)
(1,413)
8.2
Cash and cash equivalents at quarter end (item 4.6)
4,737
8.3
Unused finance facilities available at quarter end (item 7.5)
8.4
Total available funding (item 8.2 + item 8.3)
4,737
8.5
Estimated quarters of funding available (item 8.4 divided by
item 8.1)
3.35
-
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer: N/A
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer: N/A
8.6.3
Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer: N/A
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 4
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
Date:
31 October 2023
Authorised by: By the Board of Avecho Biotechnology Limited
(Name of body or officer authorising release – see note 4)
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4.
If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5.
If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 5
Share your feedback
Discover